Ubs Group Ag Kronos Bio, Inc. Transaction History

Ubs Group Ag

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$1.02 - $1.3 $21,057 - $26,838	20,645 New	20,645 $26,000
Q3 2023 Nov 09, 2023	BUY	$1.23 - $2.25 $123 - $225	100 New	100 $0
Q1 2023 May 12, 2023	BUY	$1.34 - $2.62 $5,582 - $10,914	4,166 Added 38.13%	15,091 $22,000
Q4 2022 Feb 08, 2023	BUY	$1.44 - $3.44 $15,683 - $37,465	10,891 Added 32032.35%	10,925 $17,000
Q3 2022 Nov 10, 2022	BUY	$3.35 - $5.55 $113 - $188	34 New	34 $0
Q2 2022 Aug 10, 2022	SELL	$3.12 - $7.52 $290,896 - $701,134	-93,236 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$6.26 - $14.42 $293,844 - $676,874	46,940 Added 101.39%	93,236 $674,000
Q4 2021 Feb 14, 2022	BUY	$11.35 - $21.18 $499,400 - $931,920	44,000 Added 1916.38%	46,296 $629,000
Q3 2021 Nov 15, 2021	BUY	$18.17 - $24.7 $3,634 - $4,940	200 Added 9.54%	2,296 $48,000
Q2 2021 Aug 13, 2021	BUY	$20.08 - $29.02 $1,867 - $2,698	93 Added 4.64%	2,096 $50,000
Q1 2021 May 12, 2021	SELL	$27.0 - $32.48 $8,154 - $9,808	-302 Reduced 13.1%	2,003 $59,000
Q4 2020 Feb 11, 2021	BUY	$26.68 - $38.23 $61,497 - $88,120	2,305 New	2,305 $69,000

20.7M

31.4K

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $55.1M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.